CME vs MKTX vs VRSK Stock Comparison

Cme, Marketaxess Holdings and Verisk Analytics Prices as of Nov 13, 2026 Peers: Industry group
CME Cme Group Inc.
$317.97 +11.3% 1M +12.1% 1Y
Market cap
$114.18B
P/E
25.9x
Revenue (TTM)
$6.97B
Div. yield
–
Exchanges Financial Services
6 wins
MKTX Marketaxess Holdings Inc
$165.22 +0.4% 1M -5.0% 1Y
Market cap
$5.82B
P/E
19.9x
Revenue (TTM)
$871.61M
Div. yield
0.02%
Exchanges Financial Services
4 wins
VRSK Verisk Analytics, Inc.
$207.82 +15.1% 1M -4.5% 1Y
Market cap
$27.51B
P/E
31.3x
Revenue (TTM)
$3.18B
Div. yield
–
Financial Data and Analytics Financial Services
1 win

Head to Head

11 decided of 12

Cme leads on 6 of the 12 questions below (Cme 6, Marketaxess Holdings 4, Verisk Analytics 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionCMEMKTXVRSKLeader
Larger companyMarket capitalisation $114.18B $5.82B $27.51B CME
Cheaper on earningsLower P/E, profitable companies only 25.9x 19.9x 31.3x MKTX
Cheaper on forward earningsLower price / next fiscal year consensus EPS 27.1x 20.3x 26.1x MKTX
Faster revenue growthRevenue growth, trailing twelve months +9.0% +3.9% +4.9% CME
More profitableNet margin, trailing twelve months 63.3% 33.5% 27.7% CME
Better return on capitalReturn on invested capital 11.7% 21.1% 31.9% VRSK
Less leveragedLower net debt / EBITDA 0.2x -0.7x 2.3x MKTX
Higher dividend yieldTrailing dividend yield 0.00% 0.02% 0.00% –
Better 1-year returnPrice return, last 12 months +12.1% -5.0% -4.5% CME
Better 5-year returnAnnualised price return, 5 years +7.2%/yr -15.7%/yr -0.8%/yr CME
Less volatileAnnualised volatility, 1 year 25.5% 35.9% 36.4% CME
Higher overall scoreMean of the five percentile scores vs peers 63/100 66/100 54/100 MKTX

Percentile Scorecard

CMEMKTXVRSK

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisCMEMKTXVRSK
Valuation 53 #63 of 134 73 #37 of 134 37 #699 of 1108
Growth 30 #59 of 84 27 #62 of 84 40 #540 of 897
Profitability 87 #12 of 88 95 #5 of 88 95 #46 of 922
Financial Health 51 #75 of 151 91 #15 of 151 27 #798 of 1098
Shareholder Returns 92 #5 of 49 46 #27 of 49 70 #230 of 758
Overall 63 66 54
  • CME ranked among 158 companies in Capital Markets
  • MKTX ranked among 158 companies in Capital Markets
  • VRSK ranked among 1,197 companies in Financial Services

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodCMEMKTXVRSKSPY
1 month +11.3%+0.4%+15.1% -2.0%
3 months +17.9%+1.6%+14.4% -2.8%
6 months +6.4%+19.3%+27.8% +2.0%
Year to date +16.4%-8.8%-7.1% +10.6%
1 year +12.1%-5.0%-4.5% +12.2%
3 years +50.2%-27.6%-12.7% +68.1%
3 years, per year +14.5%-10.2%-4.4% +18.9%
5 years +41.4%-57.5%-3.9% +61.4%
5 years, per year +7.2%-15.7%-0.8% +10.1%
10 years +178.0%+2.0%+150.0% +248.5%
10 years, per year +10.8%+0.2%+9.6% +13.3%

Risk

MeasureCMEMKTXVRSKSPY
Volatility, 1Y 25.5%35.9%36.4% 13.6%
Downside volatility, 1Y 27.2%27.5%36.8% 13.9%
Beta vs S&P 500, 1Y -0.300.19-0.58 1.00
Return / volatility, 1Y 0.48-0.14-0.12 0.90
Max drawdown, 5Y -33.1%-73.7%-51.2% -25.4%
From 52-week high -2.6%-14.7%-7.7% -3.2%
52-week high $326.46$193.61$225.07 $779.14
52-week low $218.58$109.09$156.84 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleCMEMKTXVRSK
P/E now vs peer median 25.8xmedian 42.3x 19.9xmedian 42.3x 30.5xmedian 14.9x
P/S now vs peer median 16.3xmedian 3.9x 6.7xmedian 3.9x 8.4xmedian 3.2x
EV/EBITDA now vs peer median 23.4xmedian 12.7x 13.2xmedian 12.7x 17.5xmedian 6.3x
P/FCF now vs peer median 26.2xmedian 16.5x 16.5xmedian 16.5x 24.2xmedian 10.5x
P/B now vs peer median 4.3xmedian 3.7x 4.6xmedian 3.7x -23.9xmedian 1.3x
PEG now vs peer median 1.88median 0.52 2.52median 0.52 1.20median 0.89

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsCMEMKTXVRSK
Revenue $6.97B $871.61M $3.18B
Gross profit $1.37B – $2.23B
Operating income $4.58B $341.21M $1.39B
Net income $4.42B $292.85M $879.20M
Free cash flow $4.33B $352.37M $1.10B
EPS (diluted) $12.31 $8.28 $6.80
Cash & equivalents $2.20B $381.05M $556.80M
Total debt $3.43B $92.00M $4.50B
Shares (diluted) 358.64M 35.28M 129.23M
Enterprise value $102.52B $4.30B $23.69B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricCMEMKTXVRSK
P/E 25.8x 19.9x 30.5x
P/FCF 26.2x 16.5x 24.2x
P/Operating cash flow 25.7x 16.3x 19.5x
P/S 16.3x 6.7x 8.4x
P/B 4.3x 4.6x -23.9x
P/Tangible book 4.7x 4.9x -18.8x
EV/EBITDA 23.4x 13.2x 17.5x
EV/EBIT 25.1x 16.2x 21.9x
EV/Revenue 16.5x 6.3x 9.6x
EV/FCF 26.5x 15.7x 27.8x
EV/Operating cash flow 25.9x 15.5x 22.4x
PEG (3Y EPS CAGR) 1.88 2.52 1.20

Growth

14 metrics
MetricCMEMKTXVRSK
Revenue growth (1Y) 9.0% 3.9% 4.9%
Revenue CAGR (3Y) 9.2% 5.9% 6.4%
Gross profit growth (1Y) 13.2% – 5.7%
Gross profit CAGR (3Y) 12.5% – 7.8%
Operating income growth (1Y) 10.1% -1.3% 3.6%
Operating income CAGR (3Y) 12.2% 2.6% 6.2%
Net income growth (1Y) 17.3% 33.3% -4.6%
Net income CAGR (3Y) 13.1% 5.7% 20.6%
EPS growth (1Y) 19.4% 40.0% 3.3%
EPS CAGR (3Y) 13.7% 7.9% 25.5%
Operating cash flow growth (1Y) 6.4% -10.6% 1.4%
Operating cash flow CAGR (3Y) 9.3% 3.1% 8.9%
Free cash flow growth (1Y) 6.1% -10.8% -1.4%
Free cash flow CAGR (3Y) 9.4% 4.1% 11.0%

Profitability

14 metrics
MetricCMEMKTXVRSK
Gross margin 19.7% – 70.2%
EBITDA margin 70.4% 48.0% 55.0%
Operating margin 65.7% 39.1% 43.9%
Pretax margin 82.8% 40.0% 36.3%
Net margin 63.3% 33.5% 27.7%
FCF margin 62.1% 40.4% 34.6%
Operating cash flow margin 63.5% 41.0% 43.0%
Return on equity 16.6% 23.3% –
Return on assets 2.3% 12.5% 19.5%
Return on invested capital 11.7% 21.1% 31.9%
Return on capital employed 12.3% – 40.5%
Asset turnover 0.0x 0.4x 0.7x
Cash conversion (OCF / net income) 1.0x 1.2x 1.6x
Stock comp / revenue 1.4% 4.1% 1.9%

Financial Health

11 metrics
MetricCMEMKTXVRSK
Debt / assets 1.8% 4.0% 99.0%
Debt / equity 0.1x 0.1x -4.0x
Net debt / EBITDA 0.2x -0.7x 2.3x
Debt / FCF 0.8x 0.3x 4.1x
Liabilities / assets 86.2% 44.0% 124.5%
Equity / assets 13.8% 56.0% -24.5%
Interest coverage 26.2x 47.6x 6.8x
Current ratio 1.0x – 1.1x
Quick ratio 0.0x – 0.9x
Cash ratio 0.0x – 0.5x
Altman Z-score 0.59 – 7.12

Shareholder Returns

7 metrics
MetricCMEMKTXVRSK
Dividend yield 3.1% 2.3% 0.9%
Net buyback yield – 5.2% 7.0%
Shareholder yield 3.1% 7.5% 7.9%
Payout ratio (earnings) – 38.0% –
Payout ratio (FCF) – 31.6% –
Dividend growth (1Y) – -3.0% –
Dividend CAGR (3Y) – 1.0% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusCMEMKTXVRSK
Forward P/E 27.1xFY2026 20.3xFY2026 26.1xFY2026
EPS, next fiscal year $11.75FY2026 $8.13FY2026 $7.96FY2026
EPS growth, next FY +4.9%FY2026 +10.0%FY2026 +11.2%FY2026
EPS growth, the year after +19.3% +9.8% +5.3%
Revenue, next fiscal year $7.27BFY2026 $941.12MFY2026 $3.33BFY2026
Revenue growth, next FY +11.6%FY2026 +11.2%FY2026 +8.6%FY2026
Revenue growth, the year after +7.0% -2.4% +6.4%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersCMEMKTXVRSK
Held by institutions 88.9% 100.0% 97.6%
Institutions holding 1,694 394 956
Change in shares held, QoQ +0.4% +2.3% -0.4%
Institutions buying 824 189 489
Institutions selling 656 164 350
Buyers to sellers 1.26 1.15 1.40

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

CMEMKTXVRSK
CME 1.00 0.29 0.23
MKTX 0.29 1.00 0.04
VRSK 0.23 0.04 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, CME, MKTX and VRSK?

Cme (CME) is the largest by market capitalisation: Cme (CME) $114.18B, Marketaxess Holdings (MKTX) $5.82B, Verisk Analytics (VRSK) $27.51B.

Which stock is cheaper, CME, MKTX and VRSK?

Marketaxess Holdings (MKTX) trades on the lowest price-to-earnings ratio (Cme (CME) 25.9x, Marketaxess Holdings (MKTX) 19.9x, Verisk Analytics (VRSK) 31.3x). On next year's consensus earnings, Marketaxess Holdings (MKTX) is cheapest (Cme (CME) 27.1x, Marketaxess Holdings (MKTX) 20.3x, Verisk Analytics (VRSK) 26.1x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Cme (CME) grew revenue fastest over the trailing twelve months: Cme (CME) +9.0%, Marketaxess Holdings (MKTX) +3.9%, Verisk Analytics (VRSK) +4.9%.

Which company is more profitable?

Cme (CME) has the highest net margin (Cme (CME) 63.3%, Marketaxess Holdings (MKTX) 33.5%, Verisk Analytics (VRSK) 27.7%). On return on invested capital, Verisk Analytics (VRSK) leads (Cme (CME) 11.7%, Marketaxess Holdings (MKTX) 21.1%, Verisk Analytics (VRSK) 31.9%).

Which stock has performed better?

Over the past year Cme (CME) returned the most: Cme (CME) +12.1%, Marketaxess Holdings (MKTX) -5.0%, Verisk Analytics (VRSK) -4.5%. Over five years, Cme (CME) compounded fastest (Cme (CME) +7.2%/yr, Marketaxess Holdings (MKTX) -15.7%/yr, Verisk Analytics (VRSK) -0.8%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Cme (CME) 0.00%, Marketaxess Holdings (MKTX) 0.02%, Verisk Analytics (VRSK) 0.00%. Cme (CME) and Verisk Analytics (VRSK) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Cme (CME) has been the steadiest (Cme (CME) 25.5%, Marketaxess Holdings (MKTX) 35.9%, Verisk Analytics (VRSK) 36.4%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, CME, MKTX and VRSK?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Cme (CME) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.